Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 19/20 | 0.82 |
| ▸ | LMNA | P02545 | 3/20 | 0.82 |
| ▸ | CYP51A1 | Q16850 | 3/20 | 0.82 |
| ▸ | FYN | P06241 | 2/20 | 0.82 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.82 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.82 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.82 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.82 |
| ▸ | TSHR | P16473 | 2/20 | 0.82 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.82 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.82 |
| ▸ | HTR2A | P28223 | 2/20 | 0.82 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.82 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.82 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.82 |
| ▸ | PGR | P06401 | 1/20 | 0.82 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.82 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.82 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.82 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1151809 | 0.99 | CYP3A4 (0.83) | CYP3A4LMNACYP51A1FYNNR1I2 | |
| SCHEMBL1152357 | 0.94 | CYP3A4 (0.82) | CYP3A4LMNACYP51A1FYNNR1I2 | |
| SCHEMBL9664745 | 0.92 | CYP3A4 (0.82) | CYP3A4LMNACYP51A1FYNNR1I2 | |
| SCHEMBL10981252 | 0.92 | CYP3A4 (0.80) | CYP3A4LMNACYP51A1FYNNR1I2 | |
| SCHEMBL10498645 | 0.92 | CYP3A4 (0.82) | CYP3A4LMNACYP51A1FYNNR1I2 | |
| SCHEMBL11072868 | 0.92 | CYP3A4 (0.82) | CYP3A4LMNACYP51A1FYNNR1I2 | |
| SCHEMBL15927829 | 0.92 | CYP3A4 (0.84) | CYP3A4LMNACYP51A1FYNNR1I2 | |
| SCHEMBL11072879 | 0.92 | CYP3A4 (0.82) | CYP3A4LMNACYP51A1FYNNR1I2 | |
| SCHEMBL10498436 | 0.92 | CYP3A4 (0.84) | CYP3A4LMNACYP51A1FYNNR1I2 | |
| SCHEMBL10622415 | 0.92 | CYP3A4 (0.80) | CYP3A4LMNACYP51A1FYNNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND | 2013-10-31 | — | — | US | disclosed |
| US-8475804-B2 | Compositions and methods for treatment of filovirus-mediated diseases | U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) | 2013-07-02 | — | — | US | disclosed |
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | ZALICUS INC. | 2011-02-03 | — | — | US | disclosed |
| US-20100092479-A1 | Compositions and methods for treatment of viral diseases | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-04-15 | — | — | US | disclosed |
| US-4358449-A | 1-(1,3-Dioxolan-2-ylmethyl)-1H-1,2,4-triazoles and compositions | JANSSEN PHARMACEUTICA, N.V. (BE) | 1982-11-09 | — | — | US | disclosed |
| US-4335125-A | FUNGICIDES, BACTERICIDES | JANSSEN PHARMACEUTICA, N.V. (BE) | 1982-06-15 | — | — | US | disclosed |
| US-4223036-A | FUNGICIDES, BACTERICIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-09-16 | — | — | US | disclosed |
| US-4144346-A | FUNGICIDES, BACTERICIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1979-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | CYP3A4 4074/4885LMNA 156/4885CYP51A1 1221/4885 |
| US-20100092479-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, RNASE1, EIF2AK2 | CYP3A4 1741/4885LMNA 340/4885CYP51A1 1566/4885 |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | CYP3A4 4074/4885LMNA 156/4885CYP51A1 1221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.